Dr. Reddy's Laboratories
Pharmaceutical Innovation Leaders
- Total funding
- $80.0 MnSeries A
- Open roles
- 0
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company that manufactures and markets a wide range of pharmaceuticals in India and overseas. They are known for their generic medicines and active pharmaceutical ingredients.
Visit company website(opens in a new tab)- Founded
- 42 Years ago
- 1984
Company vision
Dr. Reddy's Laboratories is a global pharmaceutical company that aims to provide access to affordable and innovative medicines. With a focus on research and development, their long-term vision likely involves improving global health through high-quality, accessible healthcare solutions. Visit their website for more details on products and corporate initiatives.
Jobs at Dr. Reddy's Laboratories
Open jobs at Dr. Reddy's Laboratories
Tech Stack
Dr. Reddy's Laboratories utilizes advanced technologies and tools to enhance pharmaceutical production and operational efficiency.
SAP ERP
Enterprise Resource Planning
AWS Cloud
Cloud Computing
Tableau
Data Visualization
Apache Kafka
Data Streaming
Python
Data Analysis
JIRA
Project Management
Oracle Database
Database Management
Kubernetes
Container Orchestration
Culture & People
Company links
Awards
Dr. Reddy's Laboratories is recognized for its innovative contributions to the pharmaceutical industry, earning multiple awards in recent years.
- India Pharma Innovation of the Year Award2023
- Best Biopharma Corporate Development2022
- Golden Peacock Award for Risk Management2021
Recent news
Dr. Reddy's Laboratories Launches Generic Revlimid in US
Dr. Reddy's Laboratories Reports Strong Q2 Results
Dr. Reddy's Laboratories Acquires Mayne Pharma's US Generic Portfolio
Dr. Reddy’s Laboratories Completes Acquisition of Mayne Pharma
Dr. Reddy's Launches New Generic Drug for Migraine Relief
Dr. Reddy's Laboratories Appoints New Chief Financial Officer
Dr. Reddy's Reports Record Growth in Quarterly Revenue
Dr. Reddy's Initiates Global Marketing Campaign for its New Biologics Division